Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice run starting week of Sept 14-18.
No wonder Steve wants us to keep buying the dips.
But how much profit? If you are correct, then get a lot tomorrow.
GLTA
Part II is more downside.
Closed at 2.39 after hours. Tomorrow should be a good day.
Just went over $2.38.
I am looking forward to FDA approval, then hospitals rollout and ghen at home testing.
And no dilution either:
Read news from days ago:
Precipio Launches Covid-19 Antibody Test in its CLIA laboratory
Source: GlobeNewswire Inc.?
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has completed the internal validation of the FDA-approved COVID-19 serology antibody test in its CLIA laboratory, and has launched the test commercially to its pathology customer base (phase 1). Upon obtaining further approval for expanded use by FDA, phase 2 will broaden our distribution to POC (point-of-care) healthcare facilities including hospitals, medical centers, urgent care facilities and physician practices.
Physicians will be able to conduct a simple blood draw from each patient who wishes to be tested. The samples will be shipped overnight to Precipio’s laboratory in New Haven, where they will be received the next day, tested, and results shall be returned to the physician the same day, offering a 24-hour turnaround (subject to volume and capacity capabilities). Reimbursement is approximately $45 per test. Precipio is currently able to process 1,000 tests per day, increasing testing capacity to 10,000 tests per day by the end of Q3-20 as demand grows.
Physicians and other non-medical groups wishing to utilize our rapid testing services may contact us at covidtest@precipiodx.com, or by calling us at 203.787.7888.
While this ramp up has required a modest capital investment, management believes that the company is adequately financed, and has the appropriate access to capital for the company’s current operating cash needs, through its existing equity line. At this time, Management has not, and does not anticipate conducting a public offering in the foreseeable future.
“Providing immediate access and rapid results to our customer base is our first phase of commercializing our COVID-19 antibody test, in line with our strong level of service and commitment to our customers”, said Ilan Danieli, Precipio’s CEO. “As we continue to execute on our strategy, we aim to bring increasing value to our customers and to the company.”
Smart move by the company.
$22.15 now !!! This would be $1.10 pre-split price. Closed yesterday at $0.60. HUGE jump on patent news!
I guess it is going to speak to you a lot today since the patent news just came out:
-------------------------
Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
Source: PR Newswire (US)
SEATTLE and VANCOUVER, British Columbia, July 31, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of cytisinicline, a process for their preparation, and their use in the prevention or treatment of CNS and addictive disorders.
?
Cytisinicline is a selective partial agonist of nicotinic acetylcholine receptors (nAChRs), which underlies its activity in nicotine addiction. nACHRs are more broadly involved in a range of physiological functions, such as cognitive function, learning and memory, emotion and control of movement. The newly patented analogs provide the opportunity for selective targeting of nAChRs in the brain in order to treat a number of conditions, such as Alzheimer's disease, depression, anxiety, schizophrenia, epilepsy, Parkinson's disease and addiction.
"While smoking cessation and nicotine addiction continue to be our primary focus, it is critically important that we continue to expand our intellectual property portfolio through patent extensions and future potential indications of cytisinicline," stated Rick Stewart, Chairman and Chief Executive Officer of Achieve.
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2. Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and nature of cytisinicline clinical development activities, the potential market size for cytisinicline and the effectiveness and potential uses and benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that cytisinicline may not be effective in treating a larger breadth of diseases and addictions; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; impacts from the COVID-19 pandemic; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.
Media Contact
Glenn Silver
Email: Glenn.Silver@Finnpartners.com
Telephone: 1 646 871 8485
1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017
2 Annals of Epidemiology, Volume 25, Issue 3, 179 - 182.e1
? View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-announces-patent-granted-in-the-us-for-novel-analogs-of-cytisinicline-for-use-in-cns-and-addiction-indications-301103740.html
SOURCE Achieve Life Sciences, Inc.
Gets rid of the exchange Deficiency (D).
Purely in my opinion--> Some institutional investors are prohibited from buying stocks under $5 a share. Since the reverse split is taking place one week prior to earnings and drug update, it is my contention that the company wants as many investors to come on board after the news is announced. Then the morning after, the stock will skyrocket, but then the next day another dilution round will be announced.
I will keep this until the morning after earnings are announced and then sell at 9:40 after the big run up, before the sell-off and dilution.
my plan. GLTA.
Reverse splits can signal good news for investors or bad news. A reverse split can signal that a company is financially strong enough to be listed on an exchange. The stock price will increase enough to meet the exchange’s minimum price requirement. If you own stock in a small company that has seen increased sales and profits, the stock price should continue to rise after the reverse split.
Stocks newly listed on an exchange can attract new buyers, especially institutional investors who avoid over-the-counter and pink sheets stocks. Although you will end up owning fewer shares, they will be worth more as the price continues to rise.
Angry shorts doubling down.
Looking forward to that MOASS.
August 6 earnings coming up with a drug update too.
After the RS, then it will no longer be considered a penny stock and then more funds, etc. can buy it after the good news comes out.
RS not on the corporate website.
https://achievelifesciences.com/news/
The 2020 SRNT E-conference will be held in Lausanne, Switzerland, on 17-19 September 2020.
Earnings and drug update on August 6.
What we do know is this thing is already dead since the company is out of money. IMO.
You will find the place locked/chained and no one there to talk to.
4.95 yearly high. Two year high is 25.95
Three year high is 41.25
All time high is 141.90
Looking good so far. Crawl, walk, run, fly, rocket.
I will take a 20% move so far today. Right now at 2.60
10 days left till end of July and IND submission for COVID-19.
I wonder how high this is going to run up in anticipation of the end of July IND Submission?
End of July coming in 11 calendar days from today.
----------------
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
Source: Business Wire
Piclidenoson to be evaluated for the treatment of COVID-19 infected patients with moderate symptoms
Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today that it has amended its Phase II COVID-19 study protocol based on inputs from the U.S. Food and Drug Administration (FDA) and its Pre-Investigational New Drug (IND) fling. The Company plans to file an IND application with its completed protocol before the end of July.
Looks like it will never open. I really think they are out of cash, or worse in debt too much and possibly considering what to do next with no answers coming... IMO.
One thing is for sure, the real estate tax bills keep coming in every 6 months and need to be paid to that town for the building and land. And every month that goes by makes the mining equipment still in boxes more obsolete. Finally I believe they only bought 50 miners at most in that "bulk" purchase last year.
Again, IMO. Hey, CEO, put out a PR to prove me and other doubters wrong!
P.S. I believe the CEO is the only single employee of this company.
They said in 2019 that they would be mining "soon" too. Well here we are 3/4 year later and nothing!
Any bets on when the Amazon announcement is coming?
Looking forward to short covering this afternoon, power hour after 3 pm, afterhours increase and tomorrow morning pre market increases some more.
GLTA.
Reminds me of *CODX* back in early Feb when they announced the launch of their COVID test when the shares were about $2.
Now about four (4) months later they are near $20 a share.
Hoping for the same 10X return in the same period of time.
GLTA.
Let me guess, mining will be fully up and running by 4th quarter 2019. Oops! That date has long since passed.
Gee, 3/4 of a year later and NOTHING!
Three years ago this was peaking around $6.00 a share.
GLTA.
Seems like bitcoin hype is gone, the market is in a funk, but cannabis stocks are thriving now.
Looks like this is heading back to .0232 level or lower, perhaps retracing to at least .015 or lower...
It is going to be hard for the shorts to cover near the end of the day.
Typically the big shorts don't hold overnight.
They were shorting millions of shares this morning (Clay and his buddies).
I am wondering if there is only one employee in this company.
Yeah, a top Amazon executive is coming to this pink sheet company that currently has one (1) employee. Can't be that good of an expert. Really disappointed.
When Clay Trader shows up at night then you have to sell first thing in the morning.
Always! His goons will try hard to get this below 12 today and his stupid purple line. Relentless shorts working now.
OPTEC International Rated Speculative BUY with $5.50 PPS Target by Goldman Small Cap Research
From 1.5 years ago:
https://www.otcmarkets.com/stock/OPTI/news/OPTEC-International-Rated-Speculative-BUY-with-550-PPS-Target-by-Goldman-Small-Cap-Research?id=212536
Good point.
I love this company and this one is actually going to be selling their UVC products to combat COVID-19